1. Clinical Overview
Ticarcillin-Clavulanate is a fixed-dose, injectable combination of an extended-spectrum penicillin (Ticarcillin) and a beta-lactamase inhibitor (Clavulanic Acid). Ticarcillin is a carboxypenicillin with activity against Gram-negative bacteria, including Pseudomonas aeruginosa. Clavulanic acid irreversibly inhibits many beta-lactamase enzymes, thereby protecting Ticarcillin from degradation and extending its spectrum to include beta-lactamase-producing strains of Staphylococcus aureus, Haemophilus influenzae, Bacteroides species, and some Enterobacteriaceae. This combination is particularly valuable in the Indian context for treating severe, polymicrobial, and hospital-acquired infections where resistance is a concern.
| Onset | Duration | Bioavailability |
|---|---|---|
| Rapid, with peak serum concentrations achieved within 30-45 minutes after the end of a 30-minute intravenous infusion. | The bactericidal effect is time-dependent. Dosing intervals are typically every 4-8 hours to maintain serum concentrations above the MIC for the infecting organism. | Not applicable for oral administration. The combination is administered only via intravenous infusion, providing 100% systemic bioavailability via this route. |
2. Mechanism of Action
Ticarcillin binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis in the bacterial cell wall. This leads to the activation of autolytic enzymes in the cell wall, resulting in bacterial cell lysis and death (bactericidal). Clavulanic acid has weak intrinsic antibacterial activity but is a potent, irreversible inhibitor of many bacterial beta-lactamase enzymes (including those produced by Staphylococci, Haemophilus, Moraxella, and Bacteroides). It binds to and inactivates these enzymes, thereby protecting Ticarcillin from hydrolysis and extending its spectrum of activity.
3. Indications & Uses
- Severe Bacterial Infections caused by susceptible beta-lactamase producing organisms
- Intra-abdominal infections (peritonitis, abscess)
- Complicated Urinary Tract Infections (including pyelonephritis)
- Lower Respiratory Tract Infections (pneumonia, lung abscess, empyema)
- Septicemia
- Skin and Skin Structure Infections (diabetic foot, surgical site infections)
- Bone and Joint Infections (osteomyelitis)
4. Dosage & Administration
Adult Dosage: Standard Dose: 3.1 g (Ticarcillin 3000mg + Clavulanic Acid 100mg) IV every 4 to 6 hours. For serious systemic infections (e.g., Pseudomonas), every 4 hours is typical. Maximum daily dose is usually 18-24 g of Ticarcillin component.
Administration: For IV infusion ONLY. Reconstitute each vial with Sterile Water for Injection or compatible IV solution (e.g., 0.9% NaCl). Shake well. Further dilute in a minimum of 50-100 mL of compatible diluent (0.9% NaCl, D5W, Lactated Ringer's). Infuse over 30-40 minutes. Do not mix with aminoglycosides in the same IV line/bag due to physical incompatibility; administer separately.
5. Side Effects
Common side effects may include:
- Diarrhea or loose stools
- Nausea, vomiting
- Local reactions: Phlebitis, pain at injection site
- Skin rash (non-allergic)
- Elevated liver enzymes (transaminases)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Aminoglycosides (Gentamicin, Amikacin) | Synergistic antibacterial effect against Pseudomonas and other Gram-negatives. However, physical incompatibility when mixed in same IV line; Ticarcillin may also inactivate aminoglycosides in vitro if mixed. | Major |
| Probenecid | Blocks renal tubular secretion of Ticarcillin, increasing and prolonging its serum concentrations. May be used intentionally but increases risk of neurotoxicity. | Moderate |
| Methotrexate | Ticarcillin may decrease renal clearance of methotrexate, leading to increased methotrexate levels and toxicity (myelosuppression, mucositis). | Major |
| Oral Anticoagulants (Warfarin) | May potentiate anticoagulant effect, increasing risk of bleeding. Mechanism: Altered gut flora reducing vitamin K production, possible displacement from protein binding. | Major |
| Vecuronium, other neuromuscular blockers | May prolong neuromuscular blockade. | Moderate |
| Oral Contraceptives | Potential for reduced efficacy due to altered enterohepatic circulation; advise use of alternative non-hormonal contraception. | Moderate |
7. Patient Counselling
- Inform your doctor about any history of allergies, especially to penicillin or other antibiotics.
- Complete the full course of treatment even if you feel better, to prevent recurrence and resistance.
- Report severe diarrhea, even if it occurs weeks after stopping the antibiotic, as it may be C. difficile colitis.
- Inform all treating doctors and dentists that you are on this medication.
- Do not skip doses.
8. Toxicology & Storage
Overdose: Neurological toxicity is primary concern, especially in renal impairment. Symptoms may include neuromuscular hyperexcitability, myoclonic twitching, seizures, confusion, lethargy. Electrolyte disturbances (severe hypokalemia, hypernatremia). Bleeding manifestations due to platelet dysfunction.
Storage: Store unopened vials at controlled room temperature (15-25°C), protected from light and moisture. Keep out of reach of children. After reconstitution: The solution is stable for up to 72 hours if refrigerated (2-8°C) in appropriate IV bags. Do not freeze. Discard any unused solution after the recommended time. Always inspect the solution for particulate matter or discoloration before administration.